本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002019 证券简称：亿帆医药 公告编号：2024-058 一、担保情况概述 亿帆医药股份有限公司 （一）担保基本情况 亿帆医药股份有限公司（以下简称"公司"）因全资子公司合肥亿帆生物制 药有限公司（以下简称"亿帆制药"）业务发展需要，于近日与中国银行股份有 限公司合肥庐阳支行（以下简称"中国银行庐阳支行"）签订《保证合同》，同 意为亿帆制药向中国银行庐阳支行形成的债务提供连带责任保证，担保金额为人 民币5,000万元。 关于为全资子公司提供担保的进展公告 （二）担保的审议情况 公司于2024年4月18日召开的第八届董事会第十一次会议及2024年5月17日 召开的2023年年度股东大会，均审议通过了《关于公司及控股公司向金融机构申 请授信额度及公司合并报表范围内担保额度的议案》，本次担保事项涉及的金额 及合同签署时间在公司第八届董事会第十一次会议及2023年年度股东大会审议 批准范围内，无需再次履行审议程序。 二、被担保人基本情况 公司名称：合肥亿帆生物制药有限公司 注册时间：2016年5月23日 注 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][15] Core Views - The company reported a significant increase in revenue and profit for the first three quarters of 2024, with total revenue reaching 3.858 billion yuan, a year-on-year growth of 31.67%, and net profit attributable to shareholders of 366 million yuan, a year-on-year increase of 149.50% [3] - The growth in self-developed and introduced pharmaceutical products has been substantial, contributing to the impressive profit growth, alongside increased government subsidies and revenue from drug agency rights transfer [3][4] - The company has optimized its expense ratios significantly, with sales expense ratio at 24.93%, management expense ratio at 7.25%, and financial expense ratio at 1.29% [4] Financial Performance Summary - For the first three quarters of 2024, the company achieved a net cash flow from operating activities of 430 million yuan, a year-on-year increase of 37.27% [3] - The company expects revenue for 2024 to be 5.227 billion yuan, with a year-on-year growth of 28.49%, and net profit attributable to shareholders to be 524 million yuan, reflecting a growth of 195.0% [5][11] - The projected earnings per share (EPS) for 2024 is 0.43 yuan, with corresponding price-to-earnings (PE) ratios of 29.73 for 2024, 19.96 for 2025, and 16.76 for 2026 [5][11] Product Development and Market Expansion - The company has accelerated the global rollout of its product Yilishu, which has received approvals in multiple countries and regions, including the EU and the US [4] - The company continues to advance its research and development efforts in both chemical and traditional Chinese medicine, with several new products receiving registration certificates [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark index within the next 6 months [11]. Core Views - The company reported a revenue of 3.86 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 31.7%, and a net profit of 370 million yuan, up 149.5% year-on-year [1]. - The company has successfully launched its innovative drug Ryzneuta (亿立舒) in Germany, marking a significant step in its international expansion, with plans for further launches in the US and EU [2]. - The company is experiencing rapid growth in its research and development, focusing on breakthroughs in blood cancers, rare diseases, and solid tumors, which is expected to support long-term growth [3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 1.23 billion yuan, a 24.3% increase year-on-year, and a net profit of 110 million yuan, up 196.3% year-on-year [1]. - The gross margin and net margin for Q3 2024 were reported at 47.4% and 7.8%, respectively, with a significant improvement in net margin [1]. - The company has seven products with sales exceeding 100 million yuan, with key products contributing significantly to revenue growth [1]. Research and Development - The company has made substantial progress in R&D, with discussions with regulatory bodies regarding clinical trials for new treatments, including F-652 for acute liver failure and severe alcoholic hepatitis [3]. - The company has received registration certificates for five generic drugs and is actively pursuing further product registrations [3]. Future Projections - The report forecasts revenue growth rates of 35%, 19%, and 20% for 2024, 2025, and 2026, respectively, with net profit growth rates of 200%, 32%, and 31% for the same years [5]. - Earnings per share (EPS) are projected to be 0.45 yuan, 0.59 yuan, and 0.78 yuan for 2024, 2025, and 2026, respectively [5].

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company has demonstrated strong revenue growth, with total revenue reaching 3.858 billion yuan in the first three quarters of 2024, a year-on-year increase of 31.67%. The net profit attributable to shareholders was 366 million yuan, up 149.5% year-on-year [2]. - The innovative drug Yili Shou has made significant progress in its global rollout, with the first shipment to Germany completed on October 30, 2024. This drug is expected to drive substantial sales growth in the European market [4]. - The company's focus on a "big product" strategy has led to continued revenue growth in its pharmaceutical segment, with seven domestic products achieving sales exceeding 100 million yuan [2]. Financial Performance - For the first three quarters of 2024, the gross profit margin was 47.65%, a decrease of 2.95 percentage points year-on-year, primarily due to increased costs from the amortization of intangible assets related to self-developed pharmaceutical products [3]. - The company reported a sales expense ratio of 24.93%, a decrease of 1.7 percentage points year-on-year, and a management expense ratio of 7.25%, down 2.24 percentage points year-on-year [3]. - The forecast for net profit attributable to shareholders for 2024-2026 is 518 million, 727 million, and 968 million yuan, respectively, with growth rates of 194%, 40%, and 33% [5]. Market Position and Future Outlook - The global market for the drug Yili Shou is estimated at 7 billion USD, with peak sales potential exceeding 5 billion yuan [4]. - The company is expected to benefit from its innovative pipeline and the ongoing implementation of its "big single product" strategy, anticipating a performance turnaround in 2024 [5].

Investment Rating - The investment rating for the company is "Buy" with a 6-month target price maintained at 12.56 CNY [2][4]. Core Views - The company achieved a revenue of 3.858 billion CNY in the first three quarters of 2024, representing a year-on-year growth of 31.7%. The net profit attributable to shareholders reached 366 million CNY, up 150% year-on-year [2]. - The company’s product, Yilishu (F-627), has completed its first overseas shipment, marking a significant step in its international commercialization [3]. - The company has seen strong growth in its exclusive products, with several innovative drugs contributing significantly to its performance [4]. Financial Performance Summary - For the first three quarters of 2024, the company reported a revenue of 3.858 billion CNY, a 31.7% increase year-on-year, and a net profit of 366 million CNY, which is a 150% increase year-on-year [2]. - In Q3 2024, the company generated a revenue of 1.226 billion CNY, reflecting a 24.3% year-on-year growth, with a net profit of 113 million CNY, up 196% year-on-year [2]. - The company’s revenue forecast for 2024-2026 has been adjusted downwards to 5.201 billion CNY, 6.403 billion CNY, and 7.107 billion CNY respectively [4]. Product Development and Market Expansion - Yilishu (F-627) is the first third-generation white blood cell booster approved in China and has successfully entered the national medical insurance directory, with significant sales growth expected in 2024 [3]. - The company’s partner, Tianliyuanhe, has released early efficacy data for its investigational product A-319 in treating systemic lupus erythematosus (SLE), showing rapid effects [12]. - A-319 has demonstrated significant improvements in SLEDAI-2K scores among patients, indicating its potential in the market [12]. Market Position and Competitive Landscape - The company has seven products with sales exceeding 100 million CNY, with innovative drugs like Yilishu being the main contributors to revenue growth [4]. - The competitive landscape for A-319 is highlighted by recent global interest in CD3&CD19 T cell engagers, indicating a strong market potential for the company’s offerings [11][19]. Financial Projections - The company’s projected revenues for 2024, 2025, and 2026 are 5.201 billion CNY, 6.403 billion CNY, and 7.107 billion CNY respectively, with corresponding net profits of 500 million CNY, 720 million CNY, and 910 million CNY [8][21]. - The company’s earnings per share (EPS) is expected to improve from -0.45 CNY in 2023 to 0.41 CNY in 2024, reflecting a positive trend in profitability [21].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 3.858 billion yuan in Q3 2024, representing a year-on-year increase of 31.67%, with a net profit attributable to shareholders of 366 million yuan, up 149.50% year-on-year [1] - The company is accelerating its globalization efforts, with the launch of its innovative drug Ryzneuta® in the European market [1] - The company has shown significant improvement in operational efficiency, leading to a reduction in expense ratios despite a slight decline in gross margin [1] Financial Performance Summary - Revenue for 2024 is projected to be 51.1 billion yuan, with year-on-year growth rates of 25.6%, 18.9%, and 7.1% for 2025 and 2026 respectively [2][5] - The net profit attributable to shareholders is expected to reach 5.5 billion yuan in 2024, with a staggering year-on-year growth of 199.6% [2][5] - The gross margin is forecasted to improve from 47.8% in 2023 to 52.8% by 2026 [2][5] Cash Flow and Balance Sheet Summary - Operating cash flow is expected to increase significantly, reaching 1.317 billion yuan by 2026 [3] - Total assets are projected to grow from 115 billion yuan in 2023 to 136.48 billion yuan in 2026 [4] - The company’s total liabilities are expected to remain stable, with a slight increase from 3.245 billion yuan in 2023 to 3.702 billion yuan in 2026 [4] Key Financial Ratios - The company’s return on equity (ROE) is projected to improve from -6.7% in 2023 to 9.8% by 2026 [5] - The price-to-earnings (P/E) ratio is expected to decrease from 23.95 in 2024 to 13.27 by 2026, indicating a more attractive valuation over time [5] - The debt-to-asset ratio is projected to increase slightly from 28.2% in 2023 to 30.5% in 2024, before stabilizing [5]

Investment Rating - The report maintains a "Buy" investment rating for Yifan Pharmaceutical (002019) with a target price based on the last closing price of 11.96 [1][4]. Core Insights - Q3 performance met expectations with a significant improvement in net profit margin. The company reported a revenue of 12.26 billion yuan for Q3, representing a year-over-year increase of 24.32%, and a net profit of 1.13 billion yuan, reflecting a year-over-year growth of 196.33% [1][4]. - The growth in performance is attributed to increased revenue from new and existing pharmaceutical products, as well as higher government subsidies and income from transferring drug agency rights [1][4]. - The company has effectively controlled sales expenses, leading to a noticeable improvement in net profit margin. The gross margin for Q1-Q3 2024 was 47.65%, while the net margin was 7.98%, showing an increase of 4.53 percentage points year-over-year [1][4]. - The global commercialization of innovative drugs is actively progressing, which is expected to drive future performance. The drug Yilishu has been approved for sale in China, the US, and the EU, with anticipated sales exceeding 5 billion yuan in 2024 [1][4]. Financial Summary - For the first three quarters of 2024, the company achieved a total revenue of 38.58 billion yuan, a year-over-year increase of 31.67%, and a net profit of 3.66 billion yuan, up 149.50% year-over-year [1][4]. - The projected revenues for 2024-2026 are 53.09 billion yuan, 64.17 billion yuan, and 74.23 billion yuan, with respective year-over-year growth rates of 30.51%, 20.86%, and 15.68% [4][6]. - The expected net profits for the same period are 5.06 billion yuan, 6.77 billion yuan, and 8.60 billion yuan, with year-over-year growth rates of 191.88%, 33.77%, and 26.95% [4][6].

证券时报e公司讯，据亿帆医药消息，控股子公司亿一生物有限公司（"亿一生物"）于德国时间10月30 日成功完成了创新药物Ryzneuta®在德国市场的首批发货。 Ryzneuta®是首个在中美欧获批源于中国的第三代G-CSF，是目前国内唯一在全球申请上市的"用于预防 和治疗肿瘤患者在接受抗癌药物后出现的中性粒细胞减少症"的创新药。 此次海外市场的首批发货，将为未来境外其他市场顺利发货提供宝贵经验。 ...

Financial Performance - The company's revenue for Q3 2024 reached ¥1,226,121,751.43, an increase of 24.32% compared to the same period last year[3] - Net profit attributable to shareholders was ¥113,153,515.29, representing a significant growth of 196.33% year-over-year[3] - The net profit excluding non-recurring items increased by 278.78% to ¥72,561,252.06[3] - Year-to-date revenue reached ¥3,858,211,534.78, up 31.67% from the previous year, driven by new and existing pharmaceutical products[4] - The company reported a basic earnings per share of ¥0.09, a 200.00% increase compared to the same period last year[3] - Operating profit for the current period was ¥383,633,544.49, compared to ¥125,123,271.54 in the previous period, reflecting a significant improvement[25] - Net profit attributable to shareholders of the parent company was ¥366,380,130.89, up from ¥146,845,650.22 in the previous period, indicating a growth of 149.5%[25] - The company reported a total comprehensive income of ¥296,934,756.14 for the current period, compared to ¥126,602,162.46 in the previous period[25] - The basic earnings per share increased to ¥0.30 from ¥0.12, indicating improved profitability[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,369,758,873.71, reflecting a 7.57% increase from the end of the previous year[4] - The company’s total assets as of September 30, 2024, amounted to 12,369,758,873.71 RMB, an increase from 11,499,585,782.14 RMB at the beginning of the period[23] - The company’s total liabilities as of September 30, 2024, were 3,950,405,928.04 RMB, compared to 3,244,679,252.50 RMB at the beginning of the period[23] - The company’s long-term equity investments decreased to 678,485,929.75 RMB from 702,036,940.60 RMB at the beginning of the period[22] - The company’s intangible assets increased to 1,795,272,887.62 RMB from 1,682,766,736.54 RMB at the beginning of the period[22] Cash Flow - Cash flow from operating activities for the year-to-date increased by 37.27% to ¥353,409,624.07[5] - Cash flow from operating activities generated a net amount of ¥353,409,624.07, an increase from ¥257,455,574.19 in the previous period[27] - The company recorded a cash inflow from investment activities of ¥482,394,728.40, down from ¥1,165,805,574.10 in the previous period[27] - The net cash flow from financing activities was negative at -¥368,697,671.99, contrasting with a positive inflow of ¥5,452,331.50 in the previous period[27] - Cash and cash equivalents at the end of the period reached $899,762,155.39, up from $682,980,477.18 year-over-year[28] - The company reported a cash increase of $327,016,274.20, contrasting with a decrease of $28,645,149.23 in the same quarter last year[28] - The company’s cash outflow for debt repayment was $1,173,759,041.66, down from $1,609,834,754.59 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,435[11] - The largest shareholder, Cheng Xianfeng, holds 40.82% of the shares, totaling 496,526,307 shares[11] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 2.72% of the shares, totaling 33,102,753 shares[11] - The company has not identified any related party relationships among shareholders other than those mentioned[12] - The report indicates that Zheng Zhen holds 14,942,418 shares through a credit account, while Huang Xiaomin holds 11,061,800 shares through a credit account[12] Dividends and Distributions - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 121,639,008.50 RMB, which accounts for 48.04% of the net profit attributable to shareholders for the first half of 2024[17] - The company paid $192,954,021.33 in dividends, interest, or profit distributions, compared to $63,076,408.75 in the previous year[28] Research and Development - Research and development expenses increased to ¥182,438,180.13 from ¥175,652,095.07, showing a commitment to innovation[24] Marketing and Sales - Sales expenses rose to ¥962,031,504.27 from ¥780,288,516.31, reflecting increased marketing efforts[24] Regulatory and Compliance - The company’s subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for Mesobam Injection on August 5, 2024, from the National Medical Products Administration[16] - The company’s subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for Famotidine Injection in mid-September 2024[16] Guarantees and Contracts - The company provided guarantees for its wholly-owned subsidiary Hefei Yifan Biological Pharmaceutical Co., Ltd. on July 1, 2024, with a guarantee contract signed with China Industrial Bank[14] - The company adjusted unused guarantee limits of 20 million RMB to Hefei Yifan Biological Pharmaceutical Co., Ltd. on July 15, 2024[15] - The company also adjusted unused guarantee limits of 230 million RMB to Hefei Yifan Biological Pharmaceutical Co., Ltd. on August 19, 2024[15] Accounting and Auditing - The company has not yet audited the third-quarter report[28] - The company began implementing new accounting standards from the beginning of 2024[28]

证券代码：002019 证券简称：亿帆医药 公告编号：2024-056 亿帆医药股份有限公司 关于皮敏消胶囊获得新加坡注册批文的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司SciGen Pte. Ltd.（以 下简称"赛臻公司"）于近日收到新加坡卫生科学局（Health Sciences Authority） （以下简称"HSA"）核准签发的中成药注册批文，批准公司独家医保产品皮敏 消胶囊在新加坡上市销售。现将相关情况公告如下： 四、报备文件 《注册批准证明文件》 特此公告。 该产品功能主治为：祛风除湿，清热解毒，凉血止痒。用于急慢性荨麻疹、 急性湿疹属风热证或风热挟湿证者。 该药对于风热型或风热挟湿型急、慢性荨麻疹，急性湿疹在临床上已有显著 疗效，并已得到大量临床验证。同时，临床文献证明皮敏消胶囊还可用于治疗银 屑病、玫瑰糠疹、皮肤瘙痒症、接触性皮炎等各种皮肤病，并获得《中成药临床 应用指南-皮肤病分册》《瘾疹（荨麻疹）中医治疗专家共识》《湿疹（湿疮）中医 诊疗专家共识》《玫瑰糠疹中医治疗专家共识》 ...